A Trial of Evonail® Solution for Prevention or Treatment of Onycholysis
Not Applicable
Completed
- Conditions
- Docetaxel ChemotherapyBreast Cancer
- Interventions
- Drug: EVONAIL® solution
- Registration Number
- NCT02670603
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
This study is a prospective randomized controlled study of EVONAIL® solution for prevention or treatment of onycholysis in patients with breast cancer receiving docetaxel chemotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
- Patients with breast cancer receiving adjuvant/neoadjuvant docetaxel chemotherapy
Read More
Exclusion Criteria
- Patients with breast cancer receiving palliative docetaxel chemotherapy
- Patients having onycholysis before docetaxel treatment
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control arm EVONAIL® solution In control arm, each patient painted EVONAIL® solution on nails and periungual area twice a day after developing onycholysis grade 2. This study design allowed cross-over. Therefore, this control arm would give EVONAIL® solution after developing onlycholysis grade 2 in spite of control arm. Experimental arm EVONAIL® solution In experimental arm, each patient painted EVONAIL® solution on nails and periungual areas once a day till developing onycholysis grade 2 or more.
- Primary Outcome Measures
Name Time Method The incidence of onycholysis Gr 2 or more 12weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of